Converge Bio, a biotech startup, has secured $5.5 million in seed funding to accelerate the development of new medicines using artificial intelligence (AI) and machine learning (ML). The company aims to leverage GenAI, its proprietary platform, to improve the efficiency and accuracy of drug discovery and development. GenAI combines natural language processing, computer vision, and deep learning to analyze large datasets and identify patterns that may have been missed by humans. This approach enables Converge Bio to prioritize promising leads and optimize compound design, potentially reducing the time and cost associated with bringing new treatments to market. The funding will be used to further develop the GenAI platform, expand the company’s research team, and advance its pipeline of therapeutic candidates. With this investment, Converge Bio is poised to revolutionize the pharmaceutical industry by harnessing the power of AI to drive innovation and improve patient outcomes.
Source: https://www.calcalistech.com/ctechnews/article/ryep1psfjl